Abstract
Despite the use of heparin and aspirin, acute thrombotic events are frequent complications in a broad range of clinical settings including following surgery, during acute episodes of unstable angina, and during both mechanical and pharmacologic revascularization therapies. New antithrombotic drugs are required to interrupt thrombus formation in those clinical indications where heparin, aspirin, or their combination are of limited or insufficient benefit. The enzyme thrombin has emerged as a key target for the development of more effective antithrombotic drugs. Our studies have addressed the following questions:
-
1)
Is direct antithrombin therapy more effective than heparin in prevention of thrombosis in animal models?
-
2)
What is the basis for the improved actions of direct antithrombins?
-
3)
Can a direct antithrombin be administered to humans at levels required to obtain optimal effects? Is it well-tolerated?
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
J.M. Maraganore, P. Bourdon, J. Jablonski, K.L. Ramachandran, and J.W. Fenton II, Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin, Biochemistry 29: 7095 (1990).
L.J. Berliner, Y. Sugawara, and J.W. Fenton Il, Human a-thrombin binding to non-polymerized fibrin-Sepharose. Evidence for an anionic binding region, Biochemistry 24: 7005 (1985).
D.H. Bing, M. Cory, and Fenton II, Exosite affinity labelling of human thrombins. Similar labelling on the A chain and B chain fragments of clotting a and non-clotting 13-thrombins, J. Biol. Chem. 252: 8027 (1977).
E. Skrzypczak-Jankun, V.E. Carperos, K.G. Ravichandran, A. Tulinsky, M. Westbrook, and J.M. Maraganore, Structure of the hirugen and hirulog-1 complexes of a-thrombin, J. Mol. Biol. 221: 1379 (1991).
J.M. Maraganore, T. Oshima, F. Asai, and A. Sugitachi, Comparison of anticoagulant and antithrombotic activities of hirulog-1 and argatroban (MD-805), Thromb. Haemostas. 65: 651 (abstract) (1991).
A.B. Kelly, S.R. Hanson, B. Chao, J.M. Maraganore, and L.A.Harker, Bivalent antithrombin peptide interruption of thrombus formation in vivo, Thromb. Haemostas. 65: 735 (abstract) (1991).
L.A. Harker, and S.R. Hanson, Experimental arterial thromboembolism in baboons. Mechanisms, quantitation and pharmacologic prevention, J. Clin. Invest. 64: 559 (1979).
T.H. Muller, V. Koch, U. Gerster, and J.M. Maraganore, Hirulog, a synthetic hirudin-based peptide is superior to heparin in a porcine model of arterial thrombosis, Thromb. Haemostas. 65: 1291 (abstract) (1991).
P. Klement, J. Hirsh, J.M. Maraganore, and J. Weitz, The effect of thrombin inhibitors on tissue plasminogen activator-induced thrombolysis in a rat model, Thromb. Haemostas. 65: 735 (abstract) (1991).
J.M. Maraganore, S.K. Yao, J. McNatt, J. Edit. K. Cui, L.M. Buja, and J.T. Willerson, Hùdin-based peptidesaccelerate thrombolysis and delay
reocclusions after treatment with recombinant tissue-type plasminogen activator, Thromb. Haemostas. 65: 1188 (abstract) (1991).
R.D. Hull, G.E. Raskob, J. Hirsh, R.M. Jay, J.R.LeClerc, W.H. Geerts, D. Rosenbloom, D.L. Sackett, C. Anderson, and L. Harrison, Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal vein thrombosis, N. Engl. J. Med. 315: 1109 (1986).
D. Basu, A. Gallus, J. Hirsh, and J. Cade, A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time, N. Engl. J. Med. 287: 324 (1972).
C.T. Esmon, W.G. Owen, D.L. Duiguid, and C.M. Jackson, The action of thrombin on blood clotting factor V: conversion of factor V to a prothrombin binding protein, Biochim. Biophys. Acta 310: 289 (1973).
D. Gailani, and G.J. Broze, Factor XI-activation in a revised model of blood coagulation, Science 253: 909 (1991).
D.M. Tollefsen, J.R. Feagler, P.W. and Majerus, The binding of thrombin to the surface of platelets, J. Biol. Chem. 249: 2646 (1974).
T.K.H. Vu, D.T. Hung, V.I. Wheaton, and S.R. Coughlin, Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation, Cell 64: 1057 (1991).
K.G. Mann, R.J. Jenny, and S. Krishnaswamy, Cofactor proteins in the assembly and expression of blood clotting enzyme complexes, Annu. Rev. Biochem. 57: 915 (1988).
M.R. Buchanan, B. Boneu, F.A. Ofosu, and J. Hirsh, The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effects of heparin, 65: 98 (1985).
E. Thaler, and K. Lechner, Antithrombin III deficiency and thromboembolism, in Clinics in Haematology (Prentice CRM, ed.) vol. 10, p. 369, Saunders, Philadelphia, PA (1981).
J.M. Maraganore, B. Chao, J.I. Weitz, and J. Hirsh, Comparison of antithrombin activities of heparin and hirulog 1: Basis for improved antithrombotic propeaties of direct thrombin inhibitors, Thromb. Haemostas. 65: 829 (abstract) (1991).
D.A. Lane, J. Denton, A.M. Flynn, L. Thunberg, and U. Lindahl, U. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4, Biochem. J. 218: 725 (1984).
P.J. Hogg, and C.M. Jackson, Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: Implications for heparin efficacy, Proc. Natl. Acad. Sci. USA 86: 3619 (1989).
J.I. Weitz, M. Hudoba, D. Massel, J.M. Maraganore, and J. Hirsh, Clot-bound thrombin is protected from heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors, J. Clin. Invest. 86: 385 (1990).
M. Mirshahi, J. Soria, C. Soria, F. Faivre, H. Lu, M. Courtney, C. Roitsch, D. Tripier, and J.P. Caen, Evaluation of the inhibitors of heparin and hirudin of coagulation activation during r-tPA-induced thrombolysis, Blood 74: 1026 (1989).
R. Bar-Shavit, M. Benezra, A. Eldor, E. Hy-Am, J.W. Fenton II, G.D. Wilner, and I. Vlodaysky, Thrombin immobilized to extracellular matrix is a potent mitogen for vascular smooth muscle cells: non-enzymatic mode of action, Cell Regulation 1: 453 (1990).
A. Dawson, P. Loynds, K. Findlen, E. Levin, T. Mant, J.M. Maraganore, D. Hanson, J. Wagner, and I. Fox, Hirulog 1: a bivalent thrombin inhibitor with potent anticoagulant properties in humans, Thromb. Haemostas. 65: 830 (abstract) (1991).
M.K. Cruickshank, M.N. Levine, J. Hirsh, R. Roberts, and M. Siguenza, A standard heparin program for the management of heparin therapy, Arch. Intern. Med. 151: 333 (1991).
F.C. Church, C.W. Pratt, C.M. Noyes, T. Kalayanamit, G.B. Sherrill, R.B. Tobin, and J.B. Meade, Structural and functional properties of human a-thrombin phosphorylated alpha-thrombin, and gamma thrombin. Identification of lysyl groups in alpha thrombin that are critical for heparin and fibrin(ogen) interaction, J. Biol. Chem. 264: 18419 (1989).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer Science+Business Media New York
About this chapter
Cite this chapter
Maraganore, J.M. (1993). Pre-Clinical and Clinical Studies on Hirulog: A Potent and Specific Direct Thrombin Inhibitor. In: Claeson, G., Scully, M.F., Kakkar, V.V., Deadman, J. (eds) The Design of Synthetic Inhibitors of Thrombin. Advances in Experimental Medicine and Biology, vol 340. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-2418-6_20
Download citation
DOI: https://doi.org/10.1007/978-1-4899-2418-6_20
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-2420-9
Online ISBN: 978-1-4899-2418-6
eBook Packages: Springer Book Archive